NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.

#NICE #AZ #Lokelma #nephrology #AstraZeneca #hyperkalaemia #NHS #NICEcosteffectivenessthreshold #realworldevidence #reimbursement #NICEdraftguidance #persistenthyperkalaemia #chronickidneydisease #CKD #heartfailure #RAASinhibitors #RAASinhibitortherapies #TomKeithRoach #RWEdata
zurl.co/nl7Fy

NICE recommends wider use of Biogen MS drug via NHS NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

#neurology #NICE #Biogen #natalizumab #Tysabri #multiplesclerosis #MS #activerelapsingremittingmultiplesclerosis #biosimilar #NICEdraftguidance #Sandoz #PolpharmaBiologics #biosimilarequivalent #Tyruko #activerelapsingremittingMS #rapidlyevolvingsevereMS #biosimilarmedicines
zurl.co/tsiGu

New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments

#NHSdiabetesstrategy #GLP1 #NHS #type2diabetes #personalisedapproach #expandedaccess #GLP1agonisttherapies #NHScosts #Individualisedcare #NICEdraftguidance #NICE #SGLT2inhibitors #GLP1receptoragonists #NICEguidance #NHS10Yearplan #patientadvocacy #DiabetesUK
pharmaphorum.com/news/new-nhs...

Leqembi enters second consultation period following NICE draft guidance update - PharmaTimes NICE convenes third committee meeting for additional appraisal consideration

#biotech #neurology #neurologicaldisorders #Leqembi #lecanemab #NICEdraftguidance #NICE
#EisaiEuropeLtd #Eisai #BiogenIdecLtd #Biogen #MHRA #dementia #Alzheimersdisease #AD #costeffectiveness #NHSEngland #NHSWales #patientaccess #reimbursement #valueofmedicines
pharmatimes.com/news/leqembi...